PDS Biotechnology Corp 8-K

What Happened
PDS Biotechnology Corporation (PDSB) announced on January 22, 2026, via an 8-K (Item 8.01) and an attached press release, that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company’s lead asset, PDS0101. The company filed the press release as Exhibit 99.1 and incorporated it by reference in the 8-K.

Key Details

• USPTO issued a Notice of Allowance for PDS0101 (lead asset) — announced January 22, 2026.
• The announcement was made in an 8-K under Item 8.01 (Other Events).
• Press release is filed as Exhibit 99.1 and is part of the company’s public filing.

Why It Matters
A Notice of Allowance means the USPTO has indicated it will grant a patent for the claimed invention once required fees and formal steps are completed. For investors, this strengthens PDSB’s intellectual property position around PDS0101, which can protect commercial and development rights if and when the patent issues. This is an important legal milestone, but it is not the final issued patent — additional administrative steps remain before grant.